An observational study of alemtuzumab following fingolimod for multiple sclerosis


OBJECTIVE To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab. METHODS Patients with relapsing MS treated sequentially with fingolimod then alemtuzumab who experienced significant subsequent disease… (More)
DOI: 10.1212/NXI.0000000000000320


3 Figures and Tables

Blog articles referencing this paper

Slides referencing similar topics